Marbodin (Memantine Hydrochloride)

Memantine hydrochloride is a non‑competitive NMDA‑receptor antagonist. It blocks excessive calcium entry through the NMDA‑associated ion channel, reducing excitotoxic neuronal damage caused by overstimulation of glutamate, which contributes to the cognitive decline seen in Alzheimer’s disease.

The dosage of Marbodin is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Physicians typically start with a low dose and titrate upward, but the exact regimen should always follow the prescriber’s instructions.

Safety of memantine hydrochloride during pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Marbodin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The primary alternative for Alzheimer’s disease is the acetylcholinesterase‑inhibitor class (e.g., donepezil). While acetylcholinesterase inhibitors increase acetylcholine levels, memantine works by blocking NMDA receptors to reduce excitotoxicity. Both classes may be used together for complementary benefits, but their mechanisms and side‑effect profiles differ.

Marbodin should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Marbodin is administered orally, usually as a tablet taken with water. It can be taken with or without food, but consistency with regard to meals helps maintain stable absorption. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe allergic reactions, hallucinations or psychosis, seizures, cardiac arrhythmias, and liver injury. Patients should seek immediate medical attention if they experience rash, swelling, difficulty breathing, sudden confusion, seizures, or any signs of liver dysfunction such as jaundice.

Marbodin should be avoided in individuals with known hypersensitivity to memantine or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or those taking medications that may cause significant drug‑drug interactions without close monitoring.